The primary goal of this clinical trial is to evaluate the promoting effect of pentoxifylline on anemia correction in hemodialysis patients, and involvement of the hypoxia-inducible factor-2 alpha. While, the secondary aim is to evaluate the effect of pentoxifylline on inflammation, hepcidin and other markers of iron homeostasis in these patients. Participants in this trial will be selected to be age and sex ratio matched and will be randomly assigned into two groups. Patients in group I will receive their regular doses of erythropoietin stimulating agents and other routine treatments plus 400 mg pentoxifylline tablets twice daily with meals for 6 months. While, patients in group II will receive their regular doses of erythropoietin stimulating agents and other routine treatments.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
80
400 mg pentoxifylline tablets twice daily with meals for 6 months
Mansoura University Hospital
Al Mansurah, Egypt
Variation in Hemoglobin (Hb) levels
Time frame: 6 months
Variation in Hypoxia inducible factor-2 alpha (HIF-2α) levels
Time frame: 6 months
Variation in Transforming growth factor β1 (TGF-β1) levels
Time frame: 6 months
Variation in erythropoietin stimulating agents' (ESAs) doses
Time frame: 6 months
Variation in ESA resistance index (ESA Dose/kg/Week/Hb)
Time frame: 6 months
Variation in different inflammatory markers levels
Including levels of C-reactive protein (CRP) and Interleukin 6 (IL-6)
Time frame: 6 months
Variation in hepcidin hormone levels
Time frame: 6 months
Variation in different parameters for iron status evaluation
Including serum levels of ferritin, iron and total iron binding capacity (TIBC)
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.